An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | MicrobiomeTrials
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-07-07Est. Completion: 2032-03-29
Enrollment target: 150 participants
Locations
University of California San Diego - Moores Cancer Center, La Jolla, California, United States
Saint Johns Cancer Institute, Santa Monica, California, United States
Rocky Mountain Cancer Centers, Denver, Colorado, United States
Yale Cancer Center, New Haven, Connecticut, United States
Advanced Urology Ins Daytona Beach, Daytona Beach, Florida, United States
Emory University School of Medicine-Winship Cancer Institute, Atlanta, Georgia, United States
Associated Urological Specialists, Chicago Ridge, Illinois, United States
American Oncology Partners PA Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Mass General Hospital, Boston, Massachusetts, United States
Michigan Institute of Urology, West Bloomfield, Michigan, United States
XCancer Omaha LLC, Omaha, Nebraska, United States
Perlmutter Cancer Centre, New York, New York, United States
Associated Med Professionals of NY, Syracuse, New York, United States
Montefiore Medical Center, The Bronx, New York, United States
MidLantic Urology, Bala-Cynwyd, Pennsylvania, United States
Other microbiome trials you might be interested in